1.1
Certolizumab pegol, in combination with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor‑alpha (TNF‑alpha) inhibitor, only if:
-
disease activity is severe and
-
rituximab is contraindicated or not tolerated and
-
the company provides certolizumab pegol with the agreed patient access scheme.